8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 3, 2026·SEC
Material company update
Feb 5, 2026·SEC
Strata Critical Medical, Inc.(SRTA)Earnings, Financials & Key Ratios
SRTA•NASDAQ
$5.33
$461M mkt cap·10.7× P/E·Price updated May 6, 2026
AboutStrata Critical Medical, Inc. provides time critical logistics solutions and specialized medical services to healthcare providers across the United States. The company operates as both an air and ground transporter of human organs for transplant. The company was formerly known as Blade Air Mobility, Inc. and change its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.Show more
- Revenue$197M-20.7%
- EBITDA-$14M+49.3%
- Net Income$41M+251.4%
- EPS (Diluted)0.50+242.9%
- Gross Margin20.86%-11.9%
- EBITDA Margin-7.19%+36.1%
- Operating Margin-11.34%+16.9%
- Net Margin20.97%+291.0%
- ROE16.51%+237.9%
- ROIC-7.22%+37.0%
- Debt/Equity0.01-71.8%
SRTA Key Insights
Strata Critical Medical, Inc. (SRTA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 53.1%
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SRTA Price & Volume
Strata Critical Medical, Inc. (SRTA) stock price & volume — 10-year historical chart
Loading chart...
SRTA Growth Metrics
Strata Critical Medical, Inc. (SRTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years53.1%
3 Years10.5%
TTM-16.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM276.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.46%
Return on Capital
10 Years-12.78%
5 Years-15.62%
3 Years-15.49%
Last Year-8.28%
SRTA Recent Earnings
Strata Critical Medical, Inc. (SRTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026EPS
$0.03
Est $0.04
+175.0%
Revenue
$67M
Est $64M
+5.8%
Q2 2026
Mar 3, 2026EPS
$0.06
Est $0.01
-721.4%
Revenue
$67M
Est $60M
+10.7%
Q4 2025
Nov 10, 2025EPS
$0.06
Est $0.02
-200.0%
Revenue
$49M
Est $60M
-18.3%
Q3 2025
Aug 5, 2025EPS
$0.05
Est $0.04
-25.0%
Revenue
$71M
Est $80M
-11.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.03vs $0.04+175.0% | $67Mvs $64M+5.8% |
| Q2 2026 | Mar 3, 2026 | $0.06vs $0.01-721.4% | $67Mvs $60M+10.7% |
| Q4 2025 | Nov 10, 2025 | $0.06vs $0.02-200.0% | $49Mvs $60M-18.3% |
| Q3 2025 | Aug 5, 2025 | $0.05vs $0.04-25.0% | $71Mvs $80M-11.4% |
Based on last 12 quarters of dataView full earnings history →
SRTA Peer Comparison
Strata Critical Medical, Inc. (SRTA) competitors in Air cargo and express logistics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ENSG | 10.28B | 175.93 | 30.13 | 18.72% | 6.89% | 16.61% | 1.86 | |
 ADUS | 1.8B | 96.64 | 18.55 | 23.21% | 6.89% | 9.34% | 0.19 | |
 CCRN | 326.32M | 10.11 | -3.45 | -21.56% | -9% | -24.3% | 0.01 | |
 AMN | 810.81M | 20.98 | -8.46 | -8.49% | -3.5% | -14.67% | 1.25 | |
 TBI | 181.88M | 6.05 | -3.76 | 3.1% | -4.29% | -18.74% | 0.62 | |
 HCSG | 1.58B | 22.07 | 27.25 | 7.08% | 3.21% | 11.83% | 0.05 | |
 NRSN | 20.86M | 0.90 | -1.63 | -28.8% | 0.03 | |||
 UNH | 333.37B | 367.28 | 27.76 | 11.81% | 2.68% | 11.54% | 0.77 |
Compare SRTA vs Peers
Strata Critical Medical, Inc. (SRTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRTA Income Statement
Strata Critical Medical, Inc. (SRTA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'19 | Sep'20 | Sep'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 31.2M | 23.43M | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M | 210.22M |
| Revenue Growth % | - | -24.88% | 115.61% | 189.2% | 54.11% | 10.44% | -20.73% | -16.41% |
| Cost of Goods Sold | 26.5M | 21.11M | 40.01M | 123.84M | 183.06M | 189.77M | 156.01M | 166.95M |
| COGS % of Revenue | 84.94% | 90.07% | 79.18% | 84.76% | 81.29% | 76.31% | 79.14% | - |
| Gross Profit | 4.7M▲ 0% | 2.33M▼ 50.5% | 10.52M▲ 352.0% | 22.27M▲ 111.8% | 42.12M▲ 89.1% | 58.92M▲ 39.9% | 41.13M▼ 30.2% | 43.27M▲ 0% |
| Gross Margin % | 15.06% | 9.93% | 20.82% | 15.24% | 18.71% | 23.69% | 20.86% | 20.58% |
| Gross Profit Growth % | - | -50.48% | 352% | 111.78% | 89.1% | 39.88% | -30.2% | - |
| Operating Expenses | 16.24M | 12.69M | 34.61M | 75.8M | 110.24M | 92.84M | 63.48M | 61.01M |
| OpEx % of Revenue | 52.06% | 54.13% | 68.5% | 51.88% | 48.96% | 37.33% | 32.2% | - |
| Selling, General & Admin | 15.49M | 11.82M | 32.93M | 70.26M | 105.61M | 89.66M | 60.88M | 68.46M |
| SG&A % of Revenue | 49.65% | 50.46% | 65.17% | 48.08% | 46.9% | 36.05% | 30.88% | - |
| Research & Development | 751K | 861K | 1.68M | 5.54M | 4.63M | 3.18M | 0 | 3.07M |
| R&D % of Revenue | 2.41% | 3.67% | 3.33% | 3.79% | 2.05% | 1.28% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 2.6M | 1000K |
| Operating Income | -11.54M▲ 0% | -10.36M▲ 10.2% | -24.09M▼ 132.6% | -53.53M▼ 122.2% | -68.12M▼ 27.3% | -33.93M▲ 50.2% | -22.35M▲ 34.1% | -17.74M▲ 0% |
| Operating Margin % | -37% | -44.2% | -47.68% | -36.63% | -30.25% | -13.64% | -11.34% | -8.44% |
| Operating Income Growth % | - | 10.24% | -132.58% | -122.18% | -27.25% | 50.19% | 34.11% | - |
| EBITDA | -11.07M | -9.83M | -23.5M | -69.87M | -61.01M | -27.96M | -14.17M | -12.54M |
| EBITDA Margin % | -35.48% | -41.96% | -46.5% | -47.81% | -27.09% | -11.24% | -7.19% | -5.97% |
| EBITDA Growth % | - | 11.17% | -138.96% | -197.34% | 12.68% | 54.16% | 49.33% | 50.97% |
| D&A (Non-Cash Add-back) | 472K | 526K | 596K | -16.34M | 7.11M | 5.96M | 8.19M | 5.2M |
| EBIT | -11.54M | -10.36M | -24.09M | -53.53M | -68.12M | -33.93M | -20.07M | -17.79M |
| Net Interest Income | 703K | 199K | 460K | 3.43M | 8.44M | 7.21M | 4.24M | 2.92M |
| Interest Income | 703K | 200K | 460K | 3.43M | 8.44M | 7.21M | 4.24M | 2.92M |
| Interest Expense | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 703K | 199K | -19.6M | 25.5M | 10.57M | 6.36M | 2.29M | 3.59M |
| Pretax Income | -10.84M▲ 0% | -10.16M▲ 6.3% | -43.7M▼ 330.1% | -28.03M▲ 35.8% | -57.54M▼ 105.3% | -27.56M▲ 52.1% | -20.07M▲ 27.2% | -14.15M▲ 0% |
| Pretax Margin % | -34.74% | -43.36% | -86.48% | -19.18% | -25.55% | -11.08% | -10.18% | -6.73% |
| Income Tax | 0 | 0 | -3.64M | -772K | -1.47M | -255K | -61.41M | -61.15M |
| Effective Tax Rate % | 0% | 0% | 8.34% | 2.75% | 2.55% | 0.93% | 306.06% | 432.02% |
| Net Income | -10.84M▲ 0% | -10.16M▲ 6.3% | -40.05M▼ 294.2% | -27.26M▲ 31.9% | -56.08M▼ 105.7% | -27.31M▲ 51.3% | 41.35M▲ 251.4% | 46.99M▲ 0% |
| Net Margin % | -34.74% | -43.36% | -79.27% | -18.66% | -24.9% | -10.98% | 20.97% | 22.35% |
| Net Income Growth % | - | 6.26% | -294.21% | 31.94% | -105.71% | 51.3% | 251.42% | 276.9% |
| Net Income (Continuing) | -10.84M | -10.16M | -40.05M | -27.26M | -56.08M | -27.31M | 41.35M | -16.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.47▲ 0% | -0.81▲ 44.9% | -0.57▲ 29.6% | -0.38▲ 33.3% | -0.76▼ 100.0% | -0.35▲ 53.9% | 0.50▲ 242.9% | 0.52▲ 0% |
| EPS Growth % | - | 44.9% | 29.63% | 33.33% | -100% | 53.95% | 242.86% | 51.46% |
| EPS (Basic) | -1.47 | -0.81 | -0.57 | -0.38 | -0.76 | -0.35 | 0.50 | - |
| Diluted Shares Outstanding | 7.36M | 12.51M | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M | 90.17M |
| Basic Shares Outstanding | 7.36M | 12.51M | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M | 85.32M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
SRTA Balance Sheet
Strata Critical Medical, Inc. (SRTA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'19 | Sep'20 | Sep'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.43M | 14.38M | 294.94M | 218.13M | 206.26M | 160.74M | 126.19M | 124.14M |
| Cash & Short-Term Investments | 277.57M | 12.16M | 281.97M | 192.08M | 166.14M | 127.14M | 61.23M | 58.79M |
| Cash Only | 1.31M | 12.16M | 2.6M | 41.34M | 27.87M | 18.38M | 30.97M | 58.72M |
| Short-Term Investments | 276.26M | 0 | 279.37M | 150.74M | 138.26M | 108.76M | 30.26M | 66K |
| Accounts Receivable | 0 | 1.09M | 5.55M | 10.88M | 21M | 21.59M | 39.96M | 39.6M |
| Days Sales Outstanding | - | 17.01 | 40.08 | 27.17 | 34.05 | 31.69 | 73.98 | 63.06 |
| Inventory | 0 | 512K | 547K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 8.85 | 4.99 | - | - | - | - | - |
| Other Current Assets | -276.14M | 114K | 83K | 3.08M | 19.12M | 12.02M | 25M | 25.75M |
| Total Non-Current Assets | 276.26M | 3.34M | 40.94M | 106.9M | 88.68M | 95.93M | 199.28M | 203.47M |
| Property, Plant & Equipment | 0 | 2.5M | 2.76M | 19.73M | 26.38M | 39.79M | 39.55M | 44.28M |
| Fixed Asset Turnover | - | 9.39x | 18.32x | 7.41x | 8.54x | 6.25x | 4.98x | 5.01x |
| Goodwill | 0 | 0 | 13.33M | 39.45M | 40.37M | 41.05M | 88.21M | 88.59M |
| Intangible Assets | 0 | 533K | 24.42M | 46.37M | 20.52M | 13.65M | 47.5M | 46.31M |
| Long-Term Investments | 276.26M | 200K | 200K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 107K | 232K | 1.36M | 1.4M | 1.44M | 24.02M | 86.16M |
| Total Assets | 277.69M▲ 0% | 17.71M▼ 93.6% | 335.88M▲ 1796.0% | 325.02M▼ 3.2% | 294.94M▼ 9.3% | 256.68M▼ 13.0% | 325.47M▲ 26.8% | 327.62M▲ 0% |
| Asset Turnover | 0.11x | 1.32x | 0.15x | 0.45x | 0.76x | 0.97x | 0.61x | 0.67x |
| Asset Growth % | - | -93.62% | 1796.04% | -3.23% | -9.26% | -12.97% | 26.8% | 67.99% |
| Total Current Liabilities | 371.31K | 6.34M | 12.78M | 26.61M | 35.49M | 22.73M | 19.79M | 20.94M |
| Accounts Payable | 0 | 776K | 6.37M | 16.54M | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | 13.42 | 58.11 | 48.74 | - | - | - | 22.35 |
| Short-Term Debt | 231.37K | 1.17M | 0 | 0 | 0 | 0 | 652K | 987K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 6.84M | 6.66M | 0 | 0 |
| Other Current Liabilities | 139.94K | 3.97M | 5.98M | 6.71M | 23.86M | 12.77M | 19.14M | 19.95M |
| Current Ratio | 3.85x | 2.27x | 23.07x | 8.20x | 5.81x | 7.07x | 6.38x | 6.38x |
| Quick Ratio | 3.85x | 2.19x | 23.03x | 8.20x | 5.81x | 7.07x | 6.38x | 6.38x |
| Cash Conversion Cycle | - | 12.44 | -13.04 | - | - | - | - | 40.7 |
| Total Non-Current Liabilities | 231.37K | 291K | 31.73M | 23.93M | 25.15M | 12.01M | 26.61M | 20.95M |
| Long-Term Debt | 231.37K | 0 | 0 | 0 | 0 | 0 | 2.65M | 3.48M |
| Capital Lease Obligations | 0 | 291K | 278K | 14.97M | 19.74M | 6.02M | 0 | 8.13M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 451K | 185K | 348K | 800K |
| Other Non-Current Liabilities | 0 | 0 | 31.45M | 8.96M | 4.96M | 5.81M | 23.6M | 65.19M |
| Total Liabilities | 272.69M | 6.63M | 44.51M | 50.54M | 60.64M | 34.74M | 46.4M | 41.89M |
| Total Debt | 462.73K | 1.89M | 716K | 18.33M | 24.52M | 9.32M | 3.31M | 4.47M |
| Net Debt | -842.88K | -10.28M | -1.88M | -23.01M | -3.35M | -9.06M | -27.66M | -54.26M |
| Debt / Equity | 0.09x | 0.17x | 0.00x | 0.07x | 0.10x | 0.04x | 0.01x | 0.01x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.36x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 4.33x |
| Interest Coverage | - | -10359.00x | - | - | - | - | - | - |
| Total Equity | 5M▲ 0% | 11.08M▲ 121.6% | 291.37M▲ 2529.7% | 274.49M▼ 5.8% | 234.3M▼ 14.6% | 221.94M▼ 5.3% | 279.07M▲ 25.7% | 285.73M▲ 0% |
| Equity Growth % | - | 121.6% | 2529.7% | -5.79% | -14.64% | -5.28% | 25.74% | 74.24% |
| Book Value per Share | 0.68 | 0.89 | 4.16 | 3.85 | 3.19 | 2.86 | 3.38 | 3.17 |
| Total Shareholders' Equity | 5M | 11.08M | 291.37M | 274.49M | 234.3M | 221.94M | 279.07M | 285.73M |
| Common Stock | 132 | 3K | 7K | 7K | 7K | 7K | 7K | 7K |
| Retained Earnings | 784.78K | -37.14M | -76.42M | -103.68M | -159.75M | -186.9M | -145.55M | -143.4M |
| Treasury Stock | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -898K | 2.29M | 3.96M | 1.75M | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SRTA Cash Flow Statement
Strata Critical Medical, Inc. (SRTA) cash flow — operating, investing & free cash flow history
| Line item | Sep'19 | Sep'20 | Sep'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.3M | -10.82M | -15.62M | -37.13M | -32.35M | -2.52M | -48.91M | -48.91M |
| Operating CF Margin % | -33.02% | -46.16% | -30.9% | -25.41% | -14.37% | -1.01% | -24.81% | - |
| Operating CF Growth % | - | -5.01% | -44.34% | -137.78% | 12.88% | 92.21% | -1841.8% | -64572.31% |
| Net Income | -10.84M | -10.16M | -40.05M | -27.26M | -56.08M | -27.31M | 41.35M | 46.99M |
| Depreciation & Amortization | 472K | 526K | 596K | 5.72M | 7.11M | 5.96M | 8.19M | 9.29M |
| Stock-Based Compensation | 317K | 490K | 9.62M | 8.28M | 12.5M | 19.89M | 17.83M | 11.62M |
| Deferred Taxes | 0 | 0 | -3.64M | -772K | -1.47M | -255K | 432K | 372K |
| Other Non-Cash Items | 28K | 0 | 20.06M | -23.08M | 12.32M | 2.2M | -107.63M | -31.87M |
| Working Capital Changes | -281K | -1.67M | -2.2M | -17K | -6.74M | -3.01M | -9.08M | -9.81M |
| Change in Receivables | -165K | -591K | -414K | -5.35M | -10.25M | -998K | -12.03M | -11.37M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 9.9M | 0 | 0 | 2.38M | 2.5M |
| Cash from Investing | -1.05M | -377K | -321.34M | 79.34M | 17.09M | -1.02M | 69.75M | 44.16M |
| Capital Expenditures | -604K | -377K | -297K | -730K | -2.11M | -30.88M | -9.6M | -12.88M |
| CapEx % of Revenue | 1.94% | 1.61% | 0.59% | 0.5% | 0.94% | 12.41% | 4.87% | - |
| Acquisitions | -200K | 0 | -23.07M | -48.1M | -39K | -2.23M | -66.53M | -67.78M |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -250K | 0 | -504K | 0 | 138K | -2.11M | 216.78M | 21.47M |
| Cash from Financing | 116K | 1.18M | 332.26M | -1.08M | -76K | -5.76M | -8.91M | -8.97M |
| Debt Issued (Net) | - | 1.17M | -1.17M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | - | 0 | 119.63M | 87K | 0 | -244K | 193K | 133K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -244K | 0 | 0 |
| Other Financing | 116K | 15K | 213.79M | -1.17M | -76K | -5.51M | -9.11M | -9.11M |
| Net Change in Cash | -11.24M▲ 0% | -10.02M▲ 10.9% | -4.69M▲ 53.1% | 36.84M▲ 884.9% | -15.4M▼ 141.8% | -9.37M▲ 39.1% | 14.9M▲ 258.9% | 23.3M▲ 0% |
| Free Cash Flow | -11.16M▲ 0% | -11.2M▼ 0.3% | -16.42M▼ 46.6% | -37.86M▼ 130.6% | -34.46M▲ 9.0% | -35.51M▼ 3.1% | -58.51M▼ 64.8% | -53.36M▲ 0% |
| FCF Margin % | -35.76% | -47.77% | -32.49% | -25.91% | -15.3% | -14.28% | -29.68% | -25.38% |
| FCF Growth % | - | -0.35% | -46.64% | -130.63% | 8.99% | -3.06% | -64.75% | -107.14% |
| FCF per Share | -1.52 | -0.89 | -0.23 | -0.53 | -0.47 | -0.46 | -0.71 | -0.71 |
| FCF Conversion (FCF/Net Income) | 0.95x | 1.06x | 0.39x | 1.36x | 0.58x | 0.09x | -1.18x | -1.14x |
| Interest Paid | - | 0 | 12K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | - | 0 | 0 | 0 | 16K | 0 | 87K | 0 |
SRTA Key Ratios
Strata Critical Medical, Inc. (SRTA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -126.37% | -26.48% | -9.63% | -22.04% | -11.97% | 16.51% | 17.55% |
| Return on Invested Capital (ROIC) | -313.2% | -12.45% | -14.84% | -21.18% | -11.47% | -7.22% | -7.22% |
| Gross Margin | 9.93% | 20.82% | 15.24% | 18.71% | 23.69% | 20.86% | 20.58% |
| Net Margin | -43.36% | -79.27% | -18.66% | -24.9% | -10.98% | 20.97% | 22.35% |
| Debt / Equity | 0.17x | 0.00x | 0.07x | 0.10x | 0.04x | 0.01x | 0.01x |
| Interest Coverage | -10359.00x | - | - | - | - | - | - |
| FCF Conversion | 1.06x | 0.39x | 1.36x | 0.58x | 0.09x | -1.18x | -1.14x |
| Revenue Growth | -24.88% | 115.61% | 189.2% | 54.11% | 10.44% | -20.73% | -16.41% |
SRTA SEC Filings & Documents
Strata Critical Medical, Inc. (SRTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
SRTA Frequently Asked Questions
Strata Critical Medical, Inc. (SRTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Strata Critical Medical, Inc. (SRTA) reported $210.2M in revenue for fiscal year 2025. This represents a 574% increase from $31.2M in 2019.
Strata Critical Medical, Inc. (SRTA) saw revenue decline by 20.7% over the past year.
Yes, Strata Critical Medical, Inc. (SRTA) is profitable, generating $47.0M in net income for fiscal year 2025 (21.0% net margin).
Dividend & Returns
Strata Critical Medical, Inc. (SRTA) has a return on equity (ROE) of 16.5%. This is reasonable for most industries.
Strata Critical Medical, Inc. (SRTA) had negative free cash flow of $53.4M in fiscal year 2025, likely due to heavy capital investments.
Explore More SRTA
Strata Critical Medical, Inc. (SRTA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates